Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Prostate cancer trial proving a success
Kopper with his owners
Kopper with his owners, Matt and Heather Thompson of Maryville, Tennessee.

Trial evaluates new procedure to treat prostate cancer in dogs

A clinical trial to evaluate a new procedure for treating prostate cancer in dogs is proving to be a success.

Led by Dr Bill Culp at the UC Davis Veterinary Medical Teaching Hospital, California, the trial has been performed on six dogs so far, and early results have been promising.

The treatment is similar to a procedure in human medicine that has taken hold in the past few years for treatment of non-cancerous prostate enlargement.

Known as prostatic transarterial embolization, the treatment is emerging as a minimally invasive alternative to other prostate cancer therapies.

The procedure uses MRI and CT scans to access the prostate tumour and associated blood supply. Once the blood supply is mapped, the tumour is accessed using interventional radiology techniques, utilising fluoroscopic guidance (real time "x-rays").

Catheters are placed and the blood supply to the tumour is identified. Material is then injected into the blood vessels supplying the tumour, causing a blockage and cutting off the blood supply to the tumour. The size of the gland and tumour decrease as cells die from lack of blood.

One recipient of Dr Culp's procedure is Kopper, a 14-year-old Belgian Malinois from Tennessee.

Kopper, a retired K-9 officer, was brought to the University of Tennessee's veterinary hospital last year for treament of a paralysed larynx and megaesophagus. While at the hospital, his prostate issues were discovered. Luckily the vets there were aware of Dr. Culp's clinical trial, and referred his Kopper's owners to UC Davis for the treatement.

Dr Kulp assessed Kopper's tumour using CT and MRI images which showed signs consistent with a cancerous prismatic carcinoma. The images also showed appropriate vasculature for the embolization procedure, meaning that Kopper was a good candidate for the procedure.

Together with a colleague who performs similar procedures in humans, Dr Culp successfully performed Kopper's procedure.

Kopper returned to Tennesse within a few days and, to date, his prostate has reduced in size. The hope for Kopper and all dogs undergoing this treatment, is that a decrease in tumour size will improve the qaulity and length of life for dogs with prostate cancer.

UC Davis say that the clinical trial is ongoing and the recruitment of more dogs with naturally occurring prostate cancer is needed to help evaluate the effectiveness of the treatment as an accepted standard-of-care procedure.

Image (C) UC Davis Veterinary Medicine

Become a member or log in to add this story to your CPD history

Greyhound Board announces change to vaccination guidance

News Story 1
 The Greyhound Board of Great Britain has published new vaccination guidance, with all greyhounds registered from 1 January, 2027 required to have the L4 leptospirosis vaccination, rather than L2.

The change comes in response to the reduced availability of the 'L2' Leptospirosis vaccine across the UK, and aims to support best biosecurity practice across the racing greyhound population.

GBGB veterinary director Simon Gower, said "While rare, Leptospirosis is a serious infectious disease that can affect both dogs and humans, so it is vital that we offer our greyhounds the broadest possible protection.  

Click here for more...
News Shorts
Free webinar explores congenital heart disease in dogs

A free webinar is to provide veterinary professionals, dog breeders and pet owners an new insights into congenital heart disease.

Chris Linney, a cardiology specialist and Veterinary Cardiovascular Society (VSC) member, will present the webinar from 7.00pm to 8.30pm on Wednesday, 12 November.

Dr Linney will explore the types, causes and clinical presentation of congenital heart conditions. This will include diagnostic approaches, treatment pathways and emerging research opportunities.

The session is the third to be organised by The Kennel Club, with the VCS, following an introductory webinar and a talk on acquired heart disease. Dr Linney's webinar consists of a one-hour presentation, followed by a 30-minute question and answer session.

Dr Linney said: "This webinar will be an opportunity to deepen understanding - not just of the diseases themselves, but of how breeders, vets and owners can work together to support affected dogs and improve outcomes for future generations."

Click here to register for the webinar.